Background: People who inject drugs (PWID) account for roughly 13% of the prevalent
HIV/AIDS population outside of sub-Saharan Africa, and access to opioid substitution …

Background. The optimal time to initiate highly active antiretroviral therapy (HAART) remains
unclear. Methods. Five hundred eighty-three human immunodeficiency virus (HIV) …

The delay between testing positive for human immunodeficiency virus (HIV) and entering
medical care can be better understood by identifying variables associated with use of HIV …

Background Treating the world's 40.3 million persons currently infected with HIV/AIDS is an
international responsibility that involves unprecedented organizational challenges. Key …

We conducted this study among HIV-infected injection drug users to determine the effect of
self-reported alcohol use and prior incarceration at the time of initiating antiretroviral therapy …

Background: Among those accessing treatment, highly active antiretroviral therapy (HAART)
has transformed HIV into a chronic and manageable condition. However, high levels of …

Background In Europe, a continuous programme (SPREAD) has been in place for ten years
to study transmission of drug resistant HIV. We analysed time trends of transmitted drug …

Background People who inject drugs (PWID) are at continued risk for HIV in the US, and
experience disparities across the HIV care continuum compared to other high-risk groups …

HIV-seropositive, active injection-drug users (IDUs), compared with other HIV populations,
continue to have low rates of highly active antiretroviral therapy (HAART) use, contributing to …

Objective To determine the prevalence and behavioural correlates of HIV, HBV and HCV
infections among Indonesian prisoners and to examine the impact of voluntary counselling …